In the February 2010 issue of the NMR in Biomedicine, there was a study published by Sinclair et al. entitled
NMR-based metabolomic analysis of cerebrospinal fluid and serum in neurological diseases - a diagnostic tool?In this study, 1H nuclear magnetic resonance spectroscopy analysis was used to to evaluate the diagnostic accuracy of metabolomic biomarker profiles in neurological conditions (idiopathic intracranial hypertension (IIH), multiple sclerosis (MS) and cerebrovascular disease (CVD) compared to controls with either no neurological disease or mixed neurological diseases). The patented "
Targeted Profiling" technology of
Chenomx NMR Suite was used for the identification of the discriminating peaks in the CSF and serum spectra. They concluded that NMR spectroscopic metabolic profiling of CSF and serum can identify differences between IIH, MS, CVD and mixed neurological diseases. Metabolomics may, therefore, have the potential to be developed into a clinically useful diagnostic tool. The identification of disease-unique metabolites may also impart information on disease pathology.
To see the abstract and sign-in to read this paper
click here.
If you have published any material using Chenomx NMR Suite, please do not hesitate to
let us know so that we can mention it in this newsletter. We would love to see it!
For other publications, case studies, news, and application notes using Chenomx NMR Suite
click here.
We also recently published a new application note describing 2D total correlation spectroscopy (TOCSY) to supplement and
validate metabolic profiles obtained through targeted profiling of 1D-NMR spectra. To see it
click here.
Anyone can benefit from this powerful technology by using Chenomx metabolite profiling
services or
software.
